Latest news with #AngeliniPharma
Reuters
01-04-2025
- Business
- Reuters
Angelini Pharma still keen on deals after failed Recordati bid
MILAN, April 1 (Reuters) - Italian drugmaker Angelini Pharma is keen on M&A, even after its offer to buy bigger rival Recordati ( opens new tab fell through despite having the support of potential financial partners, its Chief Executive Sergio Marullo di Condojanni said on Tuesday Media speculation over Recordati's future rose in the second half of last year, after majority shareholder CVC Capital Partners ( opens new tab hired investment banks JP Morgan and Goldman Sachs to explore options for the drugmaker. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Some reports named Angelini Pharma as a potential buyer of CVC's 51.8% stake in Recordati, but the private equity firm in January said had not had talks with Angelini's managers or shareholders and did not foresee any. "It would have been a very big operation for us, as Recordati has a market cap of over 10 billion euros ($10.78 billion). There was a lot of interest from financial partners with whom we could have bought a controlling stake," Marullo di Condojanni said on the sidelines of conference in Milan. From Angelini's point of view, the offer was "very convincing," he said. "Perhaps we could have let it go earlier but we were very persistent," he added. Marullo di Condojanni said his group was still interested in M&A deals in Italy, where he said small, profitable players had no incentive to grow, meaning there was a lack of companies of sufficient scale to invest in innovation. ($1 = 0.9273 euros)
Yahoo
18-02-2025
- Business
- Yahoo
Epilepsy Drugs Market Research 2025-2033: Marketed Medications/Drugs, Emerging Drugs, Regulations and Reimbursement Policies, Key Players Analysis
Epilepsy Drugs Market Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Epilepsy Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Drugs market is expected to reach US$ 11.85 billion by 2033 from US$ 7.92 billion in 2024, with a CAGR of 4.57 % from 2025 to 2033. Some of the main reasons driving the market expansion are the increased prevalence of epilepsy globally, notable developments in drug discovery and innovation, greater knowledge of epilepsy and available treatments, rising healthcare costs, and better access to treatment. The growing prevalence of epilepsy and improvements in treatment research have made the epileptic pharmaceuticals industry a vital sector of the global pharmaceutical market. About 50 million individuals worldwide suffer from epilepsy, which has led to a constant need for novel therapies. Numerous anti-epileptic medications (AEDs) are available on the market, ranging from more recent, more focused treatments like levetiracetam, lamotrigine, and brivaracetam to more conventional choices like phenytoin, valproate, and carbamazepine. These medications are intended to manage seizures, enhance patients' quality of life, and lower the long-term risks of consequences from epilepsy. The goal of recent advancements in customized medicine is to address each patient's distinct genetic and biological the sector is witnessing a surge in interest in cutting-edge therapies such neuromodulation devices, gene therapies, and CBD-based treatments. It is anticipated that these methods will be crucial to the treatment of epilepsy in the future. Large pharmaceutical and biotech businesses are among the market participants making significant investments in R&D to launch next-generation AEDs. Furthermore, improvements in regulations and increased knowledge of neurological conditions are creating a favorable atmosphere for development. Many patients still struggle to control their seizures even with the availability of current medicines, underscoring the continuous need for more innovation in the epileptic medication create new and better medications to treat epilepsy, pharmaceutical companies are spending money on research and development. Due to these developments, patients now have more options and the market is growing as new medications with improved efficacy, fewer side effects, and an affordable range are introduced. For example, Angelini Pharma declared in May 2023 that it will invest an extra USD 505.5 million and make an upfront payment to JCR Pharmaceuticals Co., Ltd. in order to develop a novel epilepsy Drivers for the Epilepsy Drugs Market Expanding Product SelectionThe pharmaceutical sector has stepped up its research and development efforts in response to the growing awareness of neurological conditions, such as epilepsy. The desire to address unmet medical needs, enhance treatment outcomes, and bring reasonably priced medications and therapy choices for epilepsy is what is driving this increase in R&D investments. Almost 80% of epileptics reside in low- and middle-income nations. As a result, several top pharmaceutical companies are releasing reasonably priced epilepsy medications, which is further fueling the market's Regulatory Climate and Growing ConsciousnessThe market forecast for epilepsy medications is being positively impacted by the growing awareness of epilepsy and its treatment alternatives, as well as the strategic partnership of government agencies. 100% of nations are anticipated to have at least one operational awareness campaign or advocacy program for neurological illnesses by 2031, according to a report released by the World Health Organization (WHO) in April 2022. The market is anticipated to be driven by such initiatives by the well-known organization in the near future. Additionally, November is National Epilepsy Awareness Month (NEAM) in the United #RemoveTheFilter social media campaign, started annually by the Epilepsy Foundation, aims to dispel the stigma associated with epilepsy and give hope to individuals who are struggling. The market share of epilepsy medications is also being driven by such awareness initiatives. Furthermore, the relevant regulatory bodies are accelerating the approval of novel medications, which is contributing to the expansion of the Epilepsy PrevalenceOne of the most prevalent neurological conditions in the world, epilepsy affects people of all ages. The primary factor propelling the market's expansion is the increasing incidence of epilepsy. Furthermore, a quarter of all newly diagnosed cases of epilepsy are in children, per a Healthline report. Children account for 470,000 of the more than 3 million Americans who suffer from epilepsy. 6.3 out of 1000 instances of epilepsy occur in children. The market demand for epilepsy medications is being boosted by the sharp increase in epilepsy incidence. Furthermore, chances for the development of innovative therapies are presented by the rising incidence of drug-resistant epilepsy, in which patients do not react to standard in the Epilepsy Drugs Market Lack of Quantity of Antiepileptic DrugsThe market is constrained by a number of problems, despite the fact that epilepsy, seizures, and other chronic illnesses are becoming more common in developing nations. One of the primary factors impeding market expansion is the sharp rise in the scarcity of medical supplies. Due to a shortage of medications in pharmacies, patients are keeping these medications in storage. This has raised the stakes in the global analysis of the pharmaceutical supply chain. In the UK and other places, this terrible illness might get worse. European nations, including Britain, are uncertain about Brexit. Since the United Kingdom has a lower need for epilepsy medications, this ultimately has an impact on the Effects of Current MedicationsThe cognitive and behavioral side effects of many antiepileptic medications (AEDs), including mood swings, memory loss, and trouble focusing, can have a major negative influence on a patient's quality of life. Additionally, long-term usage of these drugs may result in bodily problems like exhaustion, weight gain, and liver damage. For vulnerable groups, such as children and the elderly, these side effects are especially worrying since they may cause more severe or detrimental reactions. AEDs with enhanced safety profiles that provide efficient seizure control while reducing cognitive, behavioral, and physical adverse effects are therefore continuously needed. For epileptic patients, safer substitutes would improve overall quality of life and treatment compliance. Company Analysis: Overview, Recent Developments, Revenue Analysis Eisai Co., Ltd. UCB Inc. H. Lundbeck A/S GW Pharmaceuticals Plc. Abbott Laboratories Alkem Laboratories Limited Bausch Health Companies Inc. GSK plc Novartis AG. Pfizer Inc. Key Attributes: Report Attribute Details No. of Pages 240 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $7.92 Billion Forecasted Market Value (USD) by 2033 $11.85 Billion Compound Annual Growth Rate 4.5% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Exploring the Disease - Background and Key Insights5.1 Introduction5.2 Causes5.3 Classification of Epilepsies5.3.1 West Syndrome5.3.2 Dravet syndrome5.3.3 Lennox-Gastaut syndrome5.3.4 Landau-Kleffner syndrome5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)5.3.6 CDKL5 deficiency disorder (CDD)5.4 Risk Factors5.5 Pathophysiology5.6 Diagnosis5.6.1 Diagnostic Guidelines5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)5.6.1.3 The French National Authority for Health (HAS): 20205.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)5.7 Treatment5.7.1 Antiepileptic Medications (AEDs)5.7.2 Receptor Blockers5.7.3 Others5.7.4 Diet Therapy5.7.5 Surgery5.7.5.1 Phase I Evaluation (Noninvasive Tests)5.7.5.2 Phase II Evaluation (Invasive Mon)5.7.6 Treatment Algorithm for Medical Condition5.7.7 Treatment Guidelines5.7.7.1 American Epilepsy Society5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines5.7.7.4 NICE Guidelines: (2022)5.7.8 Living and Coping with Epilepsy6. Global Epilepsy Drugs Market7. Market Share7.1 By Drugs Category7.2 By Seizure types7.3 By Distribution Channels7.4 By Countries8. Drugs Category8.1 First Generation Drugs8.2 Second Generation Drugs8.3 Third Generation Drugs9. Seizure Types9.1 Focal Seizures9.2 Generalized Seizures9.3 Non-Epileptic Seizures10. Distribution Channels10.1 Hospital Pharmacies10.2 Drug Stores and Retail Pharmacies10.3 Online Providers11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherland11.2.8 Turkey11.3 Asia Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa11.6 Rest of the World12. Porter's Five Forces Analysis13. SWOT Analysis14. Analysis of Marketed Medications/Drugs14.1 Key Players14.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals14.2.1 Description of Drugs14.2.2 Regulatory Milestones14.2.3 Clinical Development Process14.2.4 Safety and Efficacy14.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical14.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku14.5 NAYZILAM (midazolam) nasal spray - UCB Pharma14.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma14.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion14.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma14.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical14.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals14.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo15. Analysis of Emerging Drugs15.1 Key Cross Competition15.2 XEN1101 - Xenon Pharmaceuticals15.2.1 Description of Drug15.2.2 Clinical Research & Development15.2.3 Safety and efficacy15.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)15.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics15.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)15.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences15.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals15.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals15.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals16. Regulations and Reimbursement Policies17. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epilepsy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
